Table 2.
Clinical characteristics according to EBER status in different age groups
| Variable | AITL patients ≤ 60 y (n = 53) | AITL patients > 60 y (n = 217) | ||||
|---|---|---|---|---|---|---|
| EBER‐positive (n = 30) | EBER‐negative (n = 23) | P | EBER‐positive (n = 161) | EBER‐negative (n = 56) | P | |
| Age, median | 51.5 | 54 | .276 | 73 | 73.5 | .971 |
| Sex, male | 24/30 (80%) | 18/23 (78%) | .570 | 91/161 (57%) | 34/56 (61%) | .350 |
| Extranodal > 1 | 10/30 (33%) | 8/23 (35%) | .570 | 32/160 (20%) | 10/54 (19%) | .493 |
| Stage III/IV | 26/30 (87%) | 19/23 (83%) | .486 | 140/161 (87%) | 50/56 (89%) | .424 |
| B symptoms | 15/28 (54%) | 12/22 (55%) | .586 | 85/155 (55%) | 29/55 (53%) | .454 |
| PS > 1 | 8/30 (27%) | 5/22 (23%) | .503 | 57/154 (37%) | 19/53 (36%) | .508 |
| IPI HI/H | 11/30 (37%) | 6/22 (27%) | .341 | 113/153 (74%) | 41/52 (79%) | .301 |
| PIT groups 3/4 | 11/30 (37%) | 8/22 (36%) | .607 | 120/153 (78%) | 43/53 (81%) | .420 |
| WBC > 10 000/mm3 | 7/30 (23%) | 6/23 (26%) | .533 | 40/160 (25%) | 13/56 (23%) | .471 |
| Hb < 10.5 g/dL | 5/30 (17%) | 5/23 (22%) | .451 | 44/160 (28%) | 13/56 (23%) | .330 |
| Plate < 150 000/mm3 | 7/29 (24%) | 8/22 (36%) | .261 | 54/156 (35%) | 16/52 (31%) | .371 |
| Alb < 3.5 g/dL | 10/28 (36%) | 9/23 (39%) | .515 | 92/154 (59%) | 25/53 (47%) | .076 |
| LDH > normal | 18/30 (60%) | 14/23 (61%) | .588 | 112/159 (70%) | 40/56 (71%) | .517 |
| sIL‐2R > 4000 U/mL | 16/29 (55%) | 11/21 (52%) | .536 | 85/150 (57%) | 27/51 (53%) | .381 |
| CRP > 2.00 mg/dL | 10/28 (36%) | 3/21 (14%) | .086 | 64/154 (42%) | 25/49 (51%) | .159 |
| IgG > 1700 mg/dL | 10/22 (46%) | 9/18 (50%) | .512 | 73/129 (57%) | 17/46 (37%) | .017 |
| IgM > 200 mg/dL | 10/22 (46%) | 11/18 (61%) | .252 | 56/128 (44%) | 15/44 (34%) | .172 |
| IgA > 400 mg/dL | 6/22 (27%) | 5/18 (28%) | .623 | 53/128 (41%) | 12/44 (27%) | .067 |
| CR ratea | 12/22 (55%) | 16/20 (80%) | .077 | 59/110 (54%) | 27/45 (60%) | .293 |
| Relapse/progression | 17/30 (57%) | 20/23 (87%) | .017 | 101/161 (62%) | 41/56 (73%) | .103 |
Abbreviations: AITL, angioimmunoblastic T‐cell lymphoma; Alb, albumin; CR, complete remission; CRP, c‐reactive protein; H, high; HI, high‐intermediate; Hb, hemoglobin; IPI, international prognostic index; LDH, lactate dehydrogenase; PS, performance status; PIT, prognostic index of T‐cell lymphoma; sIL‐2R, soluble interleukin‐2 receptor; WBC, white blood cell.
a
CR rate of patients who received anthracycline‐containing combination chemotherapy.